Compare Aurora Cannabis Inc (ACB) vs Prospect Capital Corporation (PSEC) Price & Performance

Aurora Cannabis (ACB) trades at $2.71, down 4.58% on the day, with a bearish technical outlook. The company reported a net income of $1.59 million in 2025, a significant improvement from a $69 million loss in 2024, though 2026 guidance projects a net loss of $136 million. Revenue grew to $343.29 million in 2025, but faces headwinds from Canadian reimbursement pressures. Analyst consensus is mixed, with 21.43% buy, 57.14% hold, and 21.43% sell ratings.

The stock's low P/B of 0.47 suggests undervaluation, but negative profitability metrics and a projected reset year in 2027 pose risks. Investment appeal hinges on execution in high-margin international medical markets, though volatility and competitive pressures remain key concerns for shareholders.

Prospect Capital Corporation (PSEC) trades at $2.20, down 1.79% recently, with a bearish technical outlook. The stock shows mixed fundamentals with a low P/B ratio of 0.37 but concerning negative revenue and net income margins. Recent earnings have consistently beaten expectations, with Q1 2026 EPS of $0.16 exceeding the $0.1109 forecast. The company maintains regular dividend payments, recently completing a $328 million portfolio sale that generated a 4.8x return on investment.

PSEC presents a high-risk opportunity with its deep discount to NAV and 18%+ yield attracting income investors, but fundamental deterioration and analyst skepticism pose significant challenges. The bearish technical signals and negative cash flow trends suggest caution, while the company's shift toward first-lien lending may improve portfolio quality over time. Investment suitability depends on risk tolerance for BDC volatility.